Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Loxo's shares dipped 6% in premarket trading as analysts questioned the wisdom of giving up US rights to larotrectinib, which was expected to spearhead Loxo's…
The Bayer-Loxo partnership was framed as the leading commercial vehicle for tissue-agnostic precision oncology following ASCO data showing durable activity…
After Lilly's $8B acquisition of Loxo, Bayer secured full global rights to Vitrakvi and BAY 2731954 (LOXO-195), consolidating control of the tissue-agnostic…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Loxo Oncology and Bayer announced a global co-development and co-commercialization partnership for the selective TRK inhibitors larotrectinib and LOXO-195. Loxo received $400M upfront plus up to $450M in larotrectinib milestones and $200M in LOXO-195 milestones (~$1.55B total). 50/50 global development cost split; Loxo leads U.S. regulatory; Bayer leads ex-U.S. regulatory and commercialization. 50/50 U.S. profit share. Larotrectinib later approved as Vitrakvi.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Loxo Oncology, Inc. (this deal) | 2017 | $1.6B | — |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
← Browse all deals · How we score deals
More: 2017 deals · Bayer AG deals · Oncology deals